ONL Therapeutics has concluded patient enrolment in its global Phase II GALAXY clinical trial assessing xelafaslatide for geographic atrophy (GA) associated with dry age-related macular degeneration (AMD).
The study (NCT06659445) will assess the therapy’s safety and efficacy in more than 324 patients across clinical centres in Canada, Europe, and the US.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
They will receive intravitreal injections across three separate experimental cohorts. These cohorts investigate two dose concentrations administered at treatment intervals of either every 12 weeks or every 24 weeks.
The trial will evaluate the primary endpoint by measuring the expansion rate of GA lesions through fundus autofluorescence at 48 weeks. The US sites also include an active reference arm.
Patient monitoring will continue through secondary timepoints extending to 72 weeks. The trial follows a Phase Ib study (NCT04744662) that established initial safety, tolerability, and preliminary efficacy signals over six months.
ONL Therapeutics chief scientific officer David Zacks said: “Enrolling a large global trial with this many participants tells us that physicians and patients want a new approach to GA that significantly reduces treatment burden.
“GA is a relentless, irreversible disease with few approved treatments, particularly in Europe. With the potential for dosing every three to six months, xelafaslatide brings a unique and differentiated mechanism of action designed to protect key retinal cells from Fas-mediated cell death to preserve vision.”
Xelafaslatide, previously designated ONL1204, is an investigational small-molecule Fas inhibitor. It protects photoreceptors and other retinal cells from cell death driven by direct and inflammatory signalling pathways.
The therapy previously secured orphan drug designation (ODD) from the US Food and Drug Administration (FDA) for macula-off retinal detachment and completed a Phase II clinical study (NCT05730218) for this indication.
GA is an advanced stage of dry AMD that causes central visual acuity loss, affecting reading and driving.
Risk factors linked to macular degeneration include advancing age, cigarette smoking, obesity, cardiovascular habits, and genetics. The company is advancing the compound to inhibit Fas-mediated cell death and protect retinal vision.
